ArticleJournal of oral biology and craniofacial research
Integrative nanoformulation of paclitaxel, ruthenium (II), and curcumin for enhanced oral cancer cell suppression.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) often responds poorly to conventional chemotherapy. This study aimed to enhance the efficacy of paclitaxel (PTX) by co-encapsulating it with a ruthenium (II) complex (Ru-II) and curcumin nanoparticles (C-NP). Methods: C-NPs were prepared via wet milling, and Ru-II was synthesized through ligand coordination and reduction. The conjugate (CoENC-PTX) was obtained by combining PTX, Ru-II, and C-NP, followed by ultrafiltration. Characterization was performed using UV-Vis, FTIR, XRD, and HRSEM. In vitro evaluations included drug release, cytotoxicity assays on OSCC cells, live/dead cell labeling, and quantitative PCR (qPCR) analysis. Results: CoENC-PTX showed efficient encapsulation with distinct spectral, crystalline, and morphological features. Drug release exhibited a biphasic profile, with 94.8 % release in 48 h. Cytotoxicity assays indicated dose-dependent reduction in OSCC cell viability, with maximum effect at 100 μg/mL. Live/dead staining confirmed apoptosis, while qPCR revealed p53 and c-Myc overexpression, indicating apoptosis activation and cell cycle regulation. Conclusion: The PTX-Ru-II-C-NP formulation significantly improved the anticancer activity against OSCC, offering a promising synergistic approach for oral cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.